Latest Breaking News On - Tiziana life - Page 5 : comparemela.com

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing .

Williama clementiIrina kofflerTanuja chitnisPaul spencerGabriele cerroneProfessor of neurology at harvard medical schoolTiziana life sciencesTiziana life sciences ltdDrug administrationBusiness developmentHome dosing initiativeLifesci advisorsAt home dosingSafety exposureHas beenHome dosing likely

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Irina kofflerPaul spencerTiziana life sciences ltdResearch in multiple sclerosisResearch of multiple sclerosisBusiness developmentTiziana life sciencesLifesci advisorsEuropean committee for treatmentAnnounces presentationSix month safetyBiomarker dataIntranasal foralumabSix non active secondary progressiveLife sciencesEuropean committee

Tiziana Life Sciences to Participate in the H C Wainwright 25th Annual Global Investment Conference

Tiziana Life Sciences to Participate in the H C Wainwright 25th Annual Global Investment Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Paul spencerIrina kofflerBusiness developmentTiziana life sciences toTiziana life sciencesLifesci advisorsTiziana life sciences ltdLife sciencesAnnual global investmentAnnual global investment conferenceTiziana lifeInvestor relationsSci advisors

Upcoming Phase 2 Data Expected For Longeveron s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer s Sector – What To Look For - Acumen Pharmaceuticals (NASDAQ:ABOS), Biogen (NASDAQ:BIIB)

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.

United statesBiogen incAging related frailtyRelated imaging abnormalityTiziana lifeMatteo vistocco

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr Howard L Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer s Disease

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr Howard L Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Howardl weinerPaul spencerIrina kofflerGabriele cerroneTiziana life sciences ltdLifesci advisorsTiziana life sciencesAnn romney centerDrug administrationBusiness developmentInvestigational new drugProfessor howardNeurologic diseasesMass general brigham healthcare systemScientific advisory boardTiziana life